ClinicalTrials.gg

Program

Rabeprazole

Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.

Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.

Furthest: phase 4, since Sep 12, 200556 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai210 open or runningphase 3since Sep 12, 2005Aug 19, 2005none ahead
Johnson & Johnson150 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Pfizer40 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead
GlaxoSmithKline30 open or runningphase 4since May 14, 2015Sep 26, 2013none ahead
Viatris30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Lomond Therapeutics20 open or runningphase 1since May 1, 2024May 1, 2024none ahead
Torrent Pharmaceuticals20 open or runningphase 1since Nov 15, 2013Nov 15, 2013none ahead
Boehringer Ingelheim10 open or runningphase 1since May 16, 2022May 16, 2022none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 4since May 20, 2013May 20, 2013none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Jun 15, 2015Jun 15, 2015none ahead
neutec-ar-ge-san-ve-tic-a-s10 open or runningphase 4since Feb 10, 2016Feb 10, 2016none ahead
pricara-unit-of-ortho-mcneil-inc10 open or runningphase 4since Oct 7, 2005Oct 7, 2005none ahead
yungjin-pharm-co-ltd10 open or runningphase 1since Jan 7, 2021Jan 7, 2021none ahead

Also a collaborator on its studies: Ono Pharmaceutical and pierre-fabre-laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 40 studies since Aug 19, 2005.

  1. Sep 26, 2013GlaxoSmithKline's first study: phase 1 study in NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT01954043 · 23 enrolled · United States, Australia, United Kingdom
  2. Nov 15, 2013Torrent Pharmaceuticals's first studies: 2 phase 1 studies in HealthyNew to Torrent PharmaceuticalsTorrent Pharmaceuticals · NCT01990586, NCT01990378
  3. Mar 24, 2014Phase 3 study in Gastroesophageal RefluxEisai · NCT02135107 · 517 enrolled · Japan
  4. Mar 24, 2014Pfizer's first study: phase 1 study in HealthyNew to PfizerPfizer · NCT02097329 · 27 enrolled · United States
  5. Dec 4, 2014Phase 1 study in HealthyPfizer · NCT02311946 · 60 enrolled · United States
  6. May 14, 20152 phase 4 studies in Gastrointestinal DiseasesGlaxoSmithKline · NCT02605395, NCT02446483
  7. Jun 15, 2015Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02477306 · 60 enrolled · Egypt
  8. Feb 10, 2016neutec-ar-ge-san-ve-tic-a-s's first study: phase 4 study in Gastroesophageal RefluxNew to neutec-ar-ge-san-ve-tic-a-sneutec-ar-ge-san-ve-tic-a-s · NCT02689999 · 12 enrolled · Turkey
  9. Jun 16, 2017Phase 1 study in Healthy VolunteerPfizer · NCT03220191 · 12 enrolled · United States
  10. Jan 7, 2021yungjin-pharm-co-ltd's first study: phase 1 study in Gastroesophageal RefluxNew to yungjin-pharm-co-ltdyungjin-pharm-co-ltd · NCT04703868 · 88 enrolled · Korea, Republic of
  11. May 16, 2022Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT05380947 · 13 enrolled · Germany
  12. Jul 1, 2022Phase 1 study in HealthyPfizer · NCT05446142 · 18 enrolled · United States
  13. May 1, 2024Lomond Therapeutics's first study: phase 1 study in AMLNew to Lomond TherapeuticsLomond Therapeutics · NCT06399315 · 112 enrolled · Australia
  14. Jan 16, 2025Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellLomond Therapeutics · NCT06787131 · 104 enrolled · Australia

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 56 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06787131Leukemia, Lymphocytic, Chronic, B-Cell · Australia1CompletedLomond TherapeuticsJul 4, 2025104
NCT06399315AML · Australia1CompletedLomond TherapeuticsJun 30, 2025112
NCT05446142Healthy · United States1CompletedPfizerSep 30, 202218
NCT05380947Healthy · Germany1CompletedBoehringer IngelheimSep 13, 202213
NCT04703868Gastroesophageal Reflux · Korea, Republic of1Completedyungjin-pharm-co-ltdJun 1, 202188
NCT03220191Healthy Volunteer · United States1CompletedPfizerSep 3, 201712
NCT02689999Gastroesophageal Reflux · Turkey4Completedneutec-ar-ge-san-ve-tic-a-sMay 201712
NCT02477306Healthy · Egypt1CompletedGenuine Research Center, EgyptMar 201460
NCT02605395Gastrointestinal Diseases · Egypt4CompletedGlaxoSmithKlineMar 30, 201470
NCT02446483Gastrointestinal Diseases · Egypt4CompletedGlaxoSmithKlineMar 26, 201460
NCT02311946Healthy · United States1CompletedPfizerApr 201560
NCT02135107Gastroesophageal Reflux · Japan3CompletedEisaiMay 2016517
NCT02097329Healthy · United States1CompletedPfizerJun 201427
NCT01990586Healthy · India1CompletedTorrent PharmaceuticalsSep 2010
NCT01990378Healthy · India1CompletedTorrent PharmaceuticalsSep 2010
NCT01954043Neoplasms · United States, Australia, United Kingdom1CompletedGlaxoSmithKlineFeb 29, 201623
NCT01860482Esophagitis, Peptic · Korea, Republic of4CompletedChong Kun Dang PharmaceuticalMay 201539
NCT01398410Stomach Ulcer · Japan3CompletedEisaiDec 2013405
NCT01397448Stomach Ulcer · Japan3CompletedEisaiMar 2013472
NCT01241409Healthy1CompletedJohnson & JohnsonDec 201078
NCT01202071Healthy · Japan2CompletedEisaiDec 201024
NCT01186497Healthy1CompletedJohnson & JohnsonNov 201035
NCT01153659Healthy · United States1CompletedEisaiAug 201090
NCT01089543Dyspepsia · Japan2CompletedEisaiAug 2011338
NCT01101646Gastroesophageal Reflux · United States1CompletedJohnson & JohnsonSep 200836
NCT01085708Healthy1CompletedEisaiMay 201016
NCT01085695Healthy1CompletedEisaiMay 201016
NCT01008696Esophagitis, Peptic4CompletedJohnson & JohnsonAug 2008217
NCT00992589Gastroesophageal Reflux · United States, Australia, Belgium and more3CompletedJohnson & JohnsonNov 2011344
NCT00911534Gastroesophageal Reflux · United States3CompletedEisaiJul 2009305
NCT00855361Gastroesophageal Reflux · United States, Germany, Poland and more1CompletedJohnson & JohnsonDec 201169
NCT00839306Gastroesophageal Reflux · United States3CompletedEisaiAug 2009240
NCT00838526Gastroesophageal Reflux · United States3CompletedEisaiJul 31, 2009240
NCT00787891Gastroesophageal Reflux3CompletedJohnson & JohnsonJan 2011127
NCT00770913Esophagitis, Peptic · Japan3CompletedEisaiNov 2009337
NCT00747695Gastroesophageal Reflux1CompletedJohnson & Johnson31
NCT00747526Gastroesophageal Reflux · United States, Belgium, Brazil and more1CompletedJohnson & JohnsonFeb 201251
NCT00658775Gastroesophageal Reflux · United States, Argentina, Australia and more3CompletedEisaiSep 20091,069
NCT00658632Gastroesophageal Reflux · United States3CompletedEisaiApr 20091,397
NCT00658528Gastroesophageal Reflux · United States, Argentina, Australia and more3CompletedEisaiSep 20091,061
NCT00649493Healthy · United States1CompletedViatrisJun 200372
NCT00649194Healthy · United States1CompletedViatrisAug 200372
NCT00648349Healthy · United States1CompletedViatrisJun 200372
NCT00553449Gastroesophageal Reflux3CompletedJohnson & Johnson48
NCT00464308Gastroesophageal Reflux · Australia4CompletedJohnson & JohnsonMay 20081,392
NCT00378287Gastroesophageal Reflux1CompletedJohnson & Johnson37
NCT00236197Heartburn · United States3CompletedEisaiMar 2006619
NCT00236184Heartburn · United States3CompletedEisaiMar 2006629
NCT00237367Gastroesophageal Reflux4Completedpricara-unit-of-ortho-mcneil-inc52
NCT00236392Gastroesophageal Reflux3CompletedJohnson & Johnson422
NCT00216489Gastroesophageal Reflux4CompletedJohnson & Johnson191
NCT00216450Helicobacter Infections4CompletedJohnson & Johnson80
NCT00165841Gastroesophageal Reflux · United States2CompletedEisaiDec 2005200
NCT00165672Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedEisaiOct 200526
NCT00165646Non-erosive Gastroesophageal Reflux Disease · Japan3CompletedEisaiOct 2005288
NCT00132496Gastroesophageal Reflux · United States2CompletedEisaiMay 2006111

How it is read

Names in the registry

  • “Rabeprazole”, 15 entries
  • “rabeprazole”, 14 entries
  • “rabeprazole sodium”, 10 entries
  • “E3810”, 8 entries
  • “Rabeprazole sodium”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.